Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

OncoNano Medicine: Brett Giroir Appointed CEO To Advance Oncology Pipeline

14 November 2026 · By · Wire by Fusion42

Published

14 November 2026

Topic

opportunities

◆ Sectors

Biotech

◆ Geography

United States

◆ Source

Read at pulse2.com →

◆ Verified

Fusion42 · 14 November 2026 · Fusion42 review

OncoNano Medicine has appointed Brett P. Giroir as permanent CEO to advance its clinical-stage oncology pipeline focused on targeted cancer therapies using proprietary polymer platforms. Giroir brings regulatory experience and government relationships crucial for clinical development and partnerships in the oncology biotech space.

This Wire brief sits within Fusion42's coverage of Biotech.

◆ ◆ The Wire takeaway

You see a leap in OncoNano’s ability to navigate regulatory hurdles and clinch partnerships with Brett Giroir as CEO, whose background offers a direct path through government and industry. That opens new doors for advancing your oncology therapies and expanding collaboration options.

◆ Coverage

1 source · 14 Nov 2026

◆ Related on Wire

◆ Topics

Biotechoncologyleadershipclinical-developmentpartnershipsregulatory